Fintel reports that on February 4, 2025, Wolfe Research initiated coverage of Vera Therapeutics (NasdaqGM:VERA) with a ...

Wolfe Research initiated coverage of Vera Therapeutics (VERA) with an Outperform rating and $49 price target The firm is ...

Goldman Sachs analyst Paul Choi initiated coverage of Vera Therapeutics (VERA) with a Buy rating and $58 price target Following the recent ...

Goldman Sachs has initiated coverage of Vera Therapeutics (VERA) with a buy rating, citing its drug candidate atacicept and a ...

Shares of NASDAQ VERA opened at $37.48 on Tuesday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. The company has a 50 day simple moving ...

Vera Therapeutics, Inc. (NASDAQ:VERA – Free Report) – Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Vera Therapeutics in a research report issued to ...

Check the time stamp on this data. Updated AI-Generated Signals for Vera Therapeutics Inc. (VERA) available here: VERA. Type ...

Goldman Sachs has initiated coverage of Vera Therapeutics (NASDAQ:VERA) with a buy rating, citing the potential of its drug candidate atacicept and a recent pullback in the stock. The investment ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Vera Therapeutics BRISBANE, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on January 8, 2025, the Compensation Committee granted inducement ...

Vera Therapeutics BRISBANE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing ...